BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics.
- In Feb 2021, BeiGene secured an option to an exclusive license to develop, manufacture, and commercialize Boston Immune Technologies and Therapeutics, Inc. (BITT) proprietary TNFR2 antagonist antibodies including BITR-2101 in Asia (excluding Japan), Australia, and New Zealand. Under the terms, BITT received an upfront payment and potential near-term milestone payments totaling $16.6 Mn, inclusive of BeiGene’s exercise of the option to license following initial proof-of-concept studies. Additionally, following BeiGene’s exercise of the option, BITT is eligible to receive development, regulatory, and sales milestones up to $105 Mn, together with tiered royalties on any product sales in the licensed territory. BeiGene also invested $4 Mn in BITT’s Series A preferred stock financing.
- In Jan 2021, Novartis signed a strategic collaboration to in-license tislelizumab from BeiGene, in major markets outside of China. Under the terms, Novartis obtain the development and commercialization rights to tislelizumab in the United States, Canada, Mexico, the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan in exchange for an upfront payment of USD 650 Mn plus royalties and milestone payments. BeiGene will retain the rights to tislelizumab in China and other countries.
- In Jan 2021, Beigene signed strategic collaboration with Strand Therapeutics to develop and commercialize Strand ‘s mRNA treatments against solid tumors in Asia (excluding Japan), Australia, and New Zealand. Under the terms, Strand received an upfront cash of $5 Mn and will also be eligible to receive additional near-term payments totaling up to $28 Mn, inclusive of BeiGene’s exercise of its options to the two programs following initial proof-of-concept studies. Additionally, Strand is eligible to receive up to $277 Mn based upon the achievement of certain development, regulatory, and sales milestones.
- In Oct 2020, BioAtla granted BeiGene, global rights to BioAtla’s investigational CAB CTLA-4 antibody (BA3071) and plans further to pursue development of BA3071 as a monotherapy and in combination with BeiGene’s investigational anti- PD-1 antibody, tislelizumab.
- In Aug 2020, Bio-Thera grant BeiGene the right to develop, manufacture, and commercialize BAT1706 in China, including Hong Kong, Macau, and Taiwan. Bio-Thera will retain rights outside of the partnered territory. Bio-Thera will receive an upfront payment and is eligible to receive payments upon the achievement of regulatory and commercial milestones up to $165 Mn and will also be eligible to receive tiered double-digit royalties on future net product sales.
- In Jan 2020, Leap Therapeutics granted BeiGene an option to develop and commercialize Leap’s DKN-01 in the Asia Pacific Region, excluding Japan. Under the terms, Leap received an upfront cash payment of $3 Mn from BeiGene in exchange for granting BeiGene an option to an exclusive license to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand,. Additionally, Leap is eligible to receive up to $132 Mn from BeiGene based upon development, regulatory, and sales milestones. BeiGene also make a $5 Mn equity investment in Leap as part of the contemporaneous $27 Mn equity financing.
- In Nov 2019, Seattle Genetics (now Seagen) granted BeiGene an exclusive rights to develop and commercialize SEA-CD70 in Asia (except Japan). Under the terms, Seattle Genetics received an upfront payment and is eligible to receive progress-dependent milestones for a total deal value of up to $160 Mn and tiered royalties on any product sales.
- In Oct 2019, Amgen enters Into strategic collaboration with BeiGene to expand Oncology presence In China. Under the agreement, BeiGene to commercialize XGEVA® (denosumab), KYPROLIS® (carfilzomib) and BLINCYTO® (blinatumomab) in China during which time the parties will equally share profits and losses. Also, Amgen and BeiGene will collaborate to advance 20 medicines from Amgen’s innovative oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion to advance these medicines. Amgen will pay royalties to BeiGene on the sales of these products outside of China, with the exception of AMG 510, Amgen’s first-in-class KRASG12C inhibitor that is being studied as a potential treatment for solid tumors.
- In Jun 2019, BeiGene and SpringWorks Therapeutics announce the formation of MapKure LLC (a newly created entity that is jointly owned by both companies) to develop BGB-3245, an investigational, selective Next-Generation RAF kinase inhibitor. Under the terms, SpringWorks has made an equity investment into MapKure and BeiGene has contributed an exclusive royalty and milestone- bearing license to develop and commercialize BGB-3245 outside of Asia, but including rights to Japan, in exchange for a majority ownership position in MapKure.
- In June 2019, BeiGene received $150 Mn payment from Celgene for the termination of earlier 2017, signed collaboration for tislelizumab.
- In Nov 2018, BeiGene acquires exclusive development & commercial rights to Zymeworks’ bispecific candidates, ZW25 and ZW49, in Asia (excluding Japan), Australia and New Zealand and licenses for Azymetric™ and EFECT™ platforms to develop up to three bispecific antibody therapeutics globally directed to BeiGene’s targets. Under the terms, Zymeworks receive upfront payments of US$40 Mn under the ZW25 and ZW49 agreements and US$20 Mn under the platform agreement and is eligible to receive development and commercial milestone payments plus potential royalties on product sales.
- In Jan 2018, Mirati Therapeutics and BeiGene signed an exclusive license agreement for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world. Under the terms, Mirati received an upfront cash payment of $10 Mn from BeiGene. Additionally, Mirati is eligible to receive up to $123 Mn in addition based on certain development, regulatory & sales milestones as well as significant sales royalties of sitravatinib in the licensed territory.
- In July 2017, BeiGene entered into a strategic collaboration with Celgene (now part of BMS) to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, Tislelizumab/ BGB-A317, for patients with solid tumor cancers in the United States, Europe, Japan and rest of world outside Asia. BeiGene will retain exclusive rights for the development and commercialization of BGB-A317 for hematological malignancies globally and for solid tumors in Asia (with the exception of Japan). Under the terms, BeiGene received an upfront licensing fees totaling $263 Mn; and $150 Mn in equity investment representing 5.9 % equity stake in BeiGene. BeiGene is also eligible to receive up to $980 Mn in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317. BeiGene also acquired Celgene’s commercial operations in China and exclusive license to Celgene’s China cancer commercial portfolio (ABRAXANE®, REVLIMID®, VIDAZA®).
- In 2013, Merck Serono entered into an agreement with BeiGene for co-development and commercialization of BGB-290 and BGB-283 in worldwide except China.
- In Aug 2013, BeiGene entered into a collaboration agreement with GENEWIZ, Inc. to accelerate cancer biomarker discovery.
- In Oct 2011, Janssen out-licensed Intetumumab/CNTO-95 to BeiGene Ltd, for clinical development and commercialization within Australia, China, Hong Kong, New Zealand, Korea, Singapore and Taiwan. Janssen & BeiGene will co-develop CNTO-95 further.
Page 1 of 2
